ORYZON Trademark

Trademark Overview

On Friday, April 17, 2015, a trademark application was filed for ORYZON with the United States Patent and Trademark Office. The USPTO has given the ORYZON trademark a serial number of 79170803. The federal status of this trademark filing is Section 71 & 15 - ACCEPTED AND ACKNOWLEDGED as of Saturday, August 6, 2022. This trademark is owned by ORYZON GENOMICS, S.A.. The ORYZON trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Research, discovery and development of therapeutic products and diagnostic products and methods in the field of epigenetics; medical and scientific research in the field of oncological, hematological, proliferative, neurological, inflammatory, metabolic, autoimmune, cardiovascular, gastrointestinal and infectious diseases; medical research; biotechnology research; chemical research; pharmaceutical products development; research and development in the pharmaceutical and biotechnology fields; research and development of pharmaceuticals for the treatment of oncological, hematological, proliferative, neurological, inflammatory, metabolic, autoimmune, cardiovascular, gastrointestinal and infectious diseases; conducting evaluations in the field of new pharmaceuticals
oryzon

General Information

Serial Number79170803
Word MarkORYZON
Filing DateFriday, April 17, 2015
Status739 - Section 71 & 15 - ACCEPTED AND ACKNOWLEDGED
Status DateSaturday, August 6, 2022
Registration Number4916133
Registration DateTuesday, March 15, 2016
Mark Drawing3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, December 29, 2015

Trademark Statements

Description of MarkThe mark consists of the term "ORYZON", written in white stylized letters on a black rectangular background; in the center of the letter "O" is a blue dot.
Indication of Colors claimedThe color(s) black, white and blue is/are claimed as a feature of the mark.
Goods and ServicesResearch, discovery and development of therapeutic products and diagnostic products and methods in the field of epigenetics; medical and scientific research in the field of oncological, hematological, proliferative, neurological, inflammatory, metabolic, autoimmune, cardiovascular, gastrointestinal and infectious diseases; medical research; biotechnology research; chemical research; pharmaceutical products development; research and development in the pharmaceutical and biotechnology fields; research and development of pharmaceuticals for the treatment of oncological, hematological, proliferative, neurological, inflammatory, metabolic, autoimmune, cardiovascular, gastrointestinal and infectious diseases; conducting evaluations in the field of new pharmaceuticals

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, August 19, 2015
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameORYZON GENOMICS, S.A.
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressMadrid 28014
ES
Party NameORYZON GENOMICS, S.A.
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressES
Party NameORYZON GENOMICS, S.A.
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressES

Trademark Events

Event DateEvent Description
Thursday, August 13, 2015SN ASSIGNED FOR SECT 66A APPL FROM IB
Wednesday, August 19, 2015ASSIGNED TO EXAMINER
Monday, August 24, 2015NON-FINAL ACTION WRITTEN
Tuesday, August 25, 2015APPLICATION FILING RECEIPT MAILED
Saturday, September 12, 2015REFUSAL PROCESSED BY IB
Friday, August 14, 2015LIMITATION FROM ORIGINAL APPLICATION ENTERED
Wednesday, August 19, 2015NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, August 25, 2015NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Tuesday, August 25, 2015REFUSAL PROCESSED BY MPU
Tuesday, August 25, 2015NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Monday, October 19, 2015TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Monday, October 19, 2015ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, December 16, 2015NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Tuesday, December 29, 2015PUBLISHED FOR OPPOSITION
Tuesday, October 20, 2015TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, October 20, 2015CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, October 21, 2015TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, November 2, 2015APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, December 9, 2015NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, December 16, 2015NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Tuesday, December 29, 2015OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Friday, March 4, 2022TEAS SECTION 71 & 15 RECEIVED
Monday, January 4, 2016NOTIFICATION PROCESSED BY IB
Tuesday, March 15, 2016REGISTERED-PRINCIPAL REGISTER
Wednesday, June 15, 2016FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Friday, July 1, 2016FINAL DISPOSITION PROCESSED
Friday, July 1, 2016FINAL DISPOSITION NOTICE SENT TO IB
Friday, July 22, 2016FINAL DECISION TRANSACTION PROCESSED BY IB
Monday, March 15, 2021COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Friday, September 3, 2021NEW REPRESENTATIVE AT IB RECEIVED
Sunday, September 8, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Sunday, September 8, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Sunday, September 8, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Saturday, March 15, 2025COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
Tuesday, August 2, 2022CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Saturday, August 6, 2022REGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK.
Saturday, August 6, 2022NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
Saturday, February 4, 2023NEW REPRESENTATIVE AT IB RECEIVED
Thursday, May 8, 2025INTERNATIONAL REGISTRATION RENEWED

Related Keywords

oryzon research development field products cardiovascular inflammatory metabolic autoimmune gastrointestinal diseases